Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RARA | P10276 | 5/20 | 0.46 |
| ▸ | RARB | P10826 | 4/20 | 0.46 |
| ▸ | RARG | P13631 | 4/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 2/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048446 | 1.00 | MAOB (0.52) | MAOBRARARARBRARGPTPN7 | |
| SCHEMBL5047257 | 0.91 | MAOB (0.48) | MAOBGSK3BBACE1TNFRSF1AMEN1 | |
| SCHEMBL5047251 | 0.91 | MAOB (0.48) | MAOBGSK3BBACE1TNFRSF1AMEN1 | |
| SCHEMBL5047177 | 0.89 | MAOB (0.43) | MAOBGSK3BBACE1AKR1C3MEN1 | |
| SCHEMBL5047173 | 0.89 | MAOB (0.43) | MAOBGSK3BBACE1AKR1C3MEN1 | |
| SCHEMBL5048367 | 0.84 | SMN1; SMN2 (0.47) | MAOBRARARARBRARGCYP26A1 | |
| SCHEMBL5048368 | 0.84 | SMN1; SMN2 (0.47) | MAOBRARARARBRARGCYP26A1 | |
| SCHEMBL5047093 | 0.83 | RARA (0.48) | MAOBRARARARBRARGCYP26A1 | |
| SCHEMBL5047091 | 0.83 | RARA (0.48) | MAOBRARARARBRARGCYP26A1 | |
| SCHEMBL5047126 | 0.82 | RARB (0.48) | MAOBRARARARBRARGCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | MAOB 2084/4885RARA 1/4885RARB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.